Coya Therapeutics (COYA) director receives 10,000 stock options at $4.53

Rhea-AI Filing Summary

Coya Therapeutics, Inc. director Mark H. Pavao received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $4.53 per share, expire on April 9, 2036, and will vest 100% on the first anniversary of the grant date, subject to continuous service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pavao Mark H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	10,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 10,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 10,000 shares Exercise price: $4.53 per share Expiration date: April 9, 2036 +2 more

5 metrics

Option grant size 10,000 shares Stock Option (right to buy) granted to director

Exercise price $4.53 per share Conversion or exercise price of stock option

Expiration date April 9, 2036 Option term end date

Underlying shares 10,000 shares Common stock underlying the option

Post-grant derivative holdings 10,000 options Total stock options following transaction

Key Terms

Stock Option (right to buy), exercise price, continuous service, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "4.5300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continuous service financial

"Subject to continuous service, 100% of the option will vest"

vesting financial

"100% of the option will vest on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock, par value $0.0001 per share financial

"underlying_security_title: "Common Stock, par value $0.0001 per share""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pavao Mark H

(Last) (First) (Middle)

5850 SAN FELIPE ST., SUITE 500

(Street)

HOUSTON TEXAS 77057

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Coya Therapeutics, Inc. [ COYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.53	04/09/2026		A		10,000		(1)	04/09/2036	Common Stock, par value $0.0001 per share	10,000	$0	10,000	D

Explanation of Responses:

1. Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant.

	/s/ David Snyder, Attorney-in-Fact	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Coya Therapeutics (COYA) director Mark H. Pavao report in this Form 4?

Director Mark H. Pavao reported receiving a grant of stock options for 10,000 shares of Coya Therapeutics common stock. These options were granted at an exercise price of $4.53 per share and are held as a direct ownership position following the transaction.

How many Coya Therapeutics (COYA) shares are covered by the new stock options?

The new stock option grant covers 10,000 shares of Coya Therapeutics common stock. Following this grant, Mark H. Pavao holds stock options over 10,000 shares, all tied to this single award reported in the Form 4 filing.

What is the exercise price of the Coya Therapeutics (COYA) options granted to Mark H. Pavao?

The options granted to Mark H. Pavao have an exercise price of $4.53 per share. This means he can purchase Coya Therapeutics common stock at $4.53 per share once the options vest and are exercisable, subject to the award’s terms.

When do Mark H. Pavao’s Coya Therapeutics (COYA) stock options vest?

The stock options will vest 100% on the first anniversary of the grant date. Vesting is conditioned on his continuous service through that date, meaning the entire 10,000-share option becomes exercisable after one year if service continues.

What is the expiration date of the Coya Therapeutics (COYA) stock options granted?

The granted stock options expire on April 9, 2036. After this expiration date, any unexercised portion of the 10,000-share option will no longer be exercisable, according to the terms disclosed in the Form 4 filing.

Is Mark H. Pavao’s ownership in Coya Therapeutics (COYA) direct or indirect after this grant?

The Form 4 indicates that Mark H. Pavao’s ownership of the stock options is direct. The ownership code is listed as “D” for direct, and there is no referenced intermediary entity or indirect ownership structure in the disclosed transaction.